Related Experiment Video
Updated: May 22, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Full-Length Enrich c-DNA Libraries-Clear Cell-Renal Cell Carcinoma
1Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, No. 1 Jen-Ai Road First Section, Taipei 100, Taiwan.
Abstract:
Clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC, is characterized by high metastasis potential and strong resistance to traditional therapies, resulting in a poor five-year survival rate of patients. Several therapies targeted to VEGF pathway for advanced RCC have been developed, however, it still needs to discover new therapeutic targets for treating RCC. Genome-wide gene expression analyses have been broadly used to identify unknown molecular mechanisms of cancer progression. Recently, we applied the oligo-capping method to construct the full-length cDNA libraries of ccRCC and adjacent normal kidney, and analyzed the gene expression profiles by high-throughput sequencing. This paper presents a review for recent findings on therapeutic potential of MYC pathway and nicotinamide N-methyltransferase for the treatment of RCC.
Insights
Clear cell renal cell carcinoma (ccRCC) is aggressive. New therapeutic targets, including the MYC pathway and nicotinamide N-methyltransferase, show promise for treating this kidney cancer.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer subtype.
- ccRCC exhibits high metastatic potential and resistance to conventional therapies, leading to poor patient survival rates.
- While VEGF-targeted therapies exist for advanced RCC, novel therapeutic targets are urgently needed.
Purpose of the Study:
- To review recent findings on the therapeutic potential of the MYC pathway in kidney cancer treatment.
- To explore the role of nicotinamide N-methyltransferase as a potential therapeutic target for RCC.
- To identify novel molecular mechanisms driving ccRCC progression through genome-wide gene expression analysis.
Main Methods:
- Construction of full-length cDNA libraries for ccRCC and adjacent normal kidney tissue using the oligo-capping method.
- High-throughput sequencing to analyze gene expression profiles.
- Review of recent scientific literature on MYC pathway and nicotinamide N-methyltransferase in RCC.
Main Results:
- Genome-wide gene expression analysis aids in uncovering molecular mechanisms of cancer progression.
- The MYC pathway has emerged as a significant area of investigation for ccRCC therapy.
- Nicotinamide N-methyltransferase is identified as a potential novel therapeutic target for kidney cancer.
Conclusions:
- Discovering new therapeutic targets is crucial for improving outcomes in ccRCC.
- The MYC pathway and nicotinamide N-methyltransferase represent promising avenues for future kidney cancer treatments.
- Advanced gene expression profiling provides valuable insights into ccRCC pathogenesis and therapeutic strategies.
